78712-67-1

Usage

Uses

Used in Pharmaceutical Research and Development:
(E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and medicinal products, potentially contributing to the treatment of various diseases and conditions.
Used in Organic Chemistry:
In the field of organic chemistry, (E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester is employed as a versatile building block for the synthesis of a wide range of organic compounds. Its properties allow for various chemical reactions, enabling the creation of new molecules with specific functions and applications.
Used in Chemical Process Development:
(E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester plays a crucial role in the development of new chemical processes and methods. Its unique reactivity and properties make it an essential component in the design and optimization of chemical reactions, leading to more efficient and sustainable production methods.
Used in Chemical Product Manufacturing:
(E)-3-[p-Bromomethylphenyl]acrylic acid ethyl ester is utilized in the production of a wide range of chemical products, including specialty chemicals, fine chemicals, and other industrial chemicals. Its versatility and reactivity contribute to the development of innovative products with specific applications in various industries.

Upstream product

• 97585-04-1 ethyl (E)-3-(4-methylphenyl)acrylate 
• 128-08-5 N-Bromosuccinimide 
• 873-55-2 sodium benzenesulfonate 
• 88738-86-7 methyl (E)-3-[4-(bromomethyl)phenyl]prop-2-enoate 

Downstream Products

• 78712-80-8 ethyl (E)-3-[4-(imidazol-1-ylmethyl)phenyl]acrylate 
• 1115433-99-2 ethyl (E)-4-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methyl]cinnamate 
• 74002-88-3 ethyl p-(1-imidazolylmethyl) cinnamate 
• 103549-17-3 3-[p-(1H-imidazole-1-ylmethyl)phenyl]propionic acid 
• 82571-53-7 ozagrel 
• 74003-01-3 4-[p-(1-imidazolylmethyl)phenyl] butyric acid hydrochloride 
• 74002-97-4 ethyl 3-<4-(1-imidazolylmethyl)phenyl>propionate 
• 74003-15-9 4-[p-(1-imidazolylmethyl)phenyl]butyronitrile 
• 74002-98-5 3-[4-(Imidazol-1-ylmethyl)phenyl]propanol 
• 74003-16-0 3-<4-(1-imidazolylmethyl)phenyl>propyl chloride 

Relevant academic research and scientific papers

Preparation method of Ozagrel sodium

The invention discloses a preparation method of Ozagrel sodium. The method comprises the following steps: performing a bromination reaction on ethyl 4-methylcinnamate and N-bromo-succinimide by takingacetonitrile as a solvent under the triggering of azodiisobutyronitrile, so as to obtain ethyl 4-bromomethylcinnamate; performing a condensation cyclization reaction on the ethyl 4-bromomethylcinnamate and imidazole by taking sodium hydroxide as an acid-binding agent and taking tetrahydrofuran as a solvent, so as to obtain imidazole ethyl 4-methylcinnamate; performing alkali hydrolysis on the imidazole ethyl 4-methylcinnamate, so as to obtain the Ozagrel sodium. According to the preparation method, the condensation cyclization reaction is performed by taking the sodium hydroxide as the acid-binding agent and taking the tetrahydrofuran as the solvent, so that the finally obtained product does not contain toxic components, the yield and the purity of the product can be effectively improved,and the content of genotoxic impurities (the ethyl 4-bromomethylcinnamate and ethyl 4-dibromomethylcinnamate) in the product is zero.

Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors

A novel series of compounds containing a uracil moiety as the connection unit between a phenyl/phenylalkyl portion and a N-hydroxy- polymethylenealkanamide or -methylenecinnamylamide group (uracil-based hydroxamic acids, UBHAs) was tested against maize histone deacetylases (HDACs) and mouse HDAC1. Compounds with a phenyl/benzyl ring at the uracil-C6 position and bearing 4-5 carbon units as well as a m- or p-methylenecinnamyl moiety as a spacer were the most potent inhibitors. In cell-based human HDAC1 and HDAC4 assays, the two UBHAs tested inhibited the HDAC1 but not HDAC4 immunoprecipitate activity. When tested in human leukemia U937 cells, some UBHAs produced G1 phase arrest of the cell cycle. Moreover, 1j showed high antiproliferative and dose-dependent granulocytic differentiation properties. The tested UBHAs displayed weak p21WAF1/CIP1 induction in U937 cells, and 1d and 1j showed high histone H3 and α-tubulin acetylation effects.

Sulfone compounds

The invention relates to novel sulfone compounds of formula I STR1 wherein R1 is an unsubstituted or substituted phenyl or naphthyl radical, R2 is hydrogen or the radical of the formula STR2 R3 and R4 are --CN o

11,12-Secoprostaglandins. 6. Interphenylene Analogues of Acylhydroxyalkanoic Acids and Related Compounds as Renal Vasodilators

The synthesis is described of a series of interphenylene analogues of the modified 11,12-secoprostaglandins and their sulfonamide isosteres on which we have reported previously.The new compounds are formally derived from members of earlier series by replacement of segments of the methylene chains by phenylene units.Several of these compounds displayed renal vasodilatory activity on iv stat administration to anesthetized dogs. 4-(4-Acetyl-8-hydroxytridecyl)benzoic acid tested additionally in conscious dogs orally caused a significant increase in renal blood flow at 5 mg/kg.

Interphenylene 11,12-secoprostaglandins

Novel interphenylene derivatives of 11,12-secoprostaglandins are prepared by the stepwise alkylation of the ethyl ester or the t-butyl ester of acetoacetic acid. One such method involves treatment of the t-butyl ester of acetoacetic acid with a strong base to form the anion followed by treatment with ethyl p-(3-bromopropyl)benzoate to produce ethyl 4-(4-tert-butoxycarbonyl-5-oxo-hexyl)benzoate, subsequently reacting the anion of the thus-formed benzoate with 1-chloro-4-acetoxynonane to produce ethyl 4-(4-acetyl-4-tert-butoxycarbonyl-8-acetoxytridecyl)benzoate followed by decarboxylation and alkaline hydrolysis to produce the desired product 4-(4-acetyl-8-hydroxytridecyl)benzoic acid which is useful as a pharmaceutical in the treatment of patients with renal failure and in the prevention of transplant rejection.